Target Name: CD300A
NCBI ID: G11314
Review Report on CD300A Target / Biomarker Content of Review Report on CD300A Target / Biomarker
CD300A
Other Name(s): CD300a | CD300a molecule, transcript variant 1 | CMRF-35-H9 | inhibitory receptor protein 60 | CMRF35H leukocyte immunoglobulin-like receptor | CMRF35H9 | CD300 antigen-like family member A | Inhibitory receptor protein 60 | CD300A variant 1 | IRC1 | IRC2 | IRC1/IRC2 | IgSF12 | CMRF-35H | IGSF12 | leukocyte membrane antigen | CD300a molecule | CMRF35-H | CMRF35-H9 | CMRF35H | CMRF35-like molecule 8 | CLM-8 | CD300a antigen | CLM8_HUMAN | CMRF35-like molecule 8 (isoform 1) | NK inhibitory receptor | Immunoglobulin superfamily member 12 | IRp60 | immunoglobulin superfamily member 12

Understanding CD300A: Potential Drug Target and Biomarker

CD300A is a protein that is expressed in a variety of tissues throughout the body, including the skin, hair, and bone marrow. It is a member of the CD300 family of proteins, which are known for their ability to interact with the protein PD-L1.

CD300A is currently being investigated as a potential drug target for the treatment of various diseases, including cancer. One of the main reasons for this is its ability to promote the development and progression of cancer.

Studies have shown that CD300A is highly expressed in a variety of cancer types, including breast, lung, and ovarian cancer. It has also been shown to play a role in the development of cancer stem cells.

In addition to its role in cancer, CD300A is also being investigated as a potential biomarker for the disease. Its expression has been shown to be associated with the severity of certain diseases, such as rheumatoid arthritis and multiple sclerosis.

Despite the promising potential of CD300A as a drug target and biomarker, much more research is needed to fully understand its role in the disease.

One of the main challenges in studying CD300A is its complex structure. While it is known to be a protein that is involved in cell signaling, it is not clear exactly how it functions in this process.

In order to fully understand the role of CD300A in cell signaling, researchers will need to study its structure and function in more detail. This will involve using a variety of techniques, including mass spectrometry and biochemical assays.

Another challenge in studying CD300A is its ability to interact with other proteins. While it is known that CD300A can interact with the protein PD-L1, it is not clear how this interaction contributes to its function.

In order to fully understand how CD300A functions, researchers will need to study its interactions with other proteins in more detail. This will involve using techniques such as biochemical assays and mass spectrometry.

CD300A is also known to be involved in the development of cancer stem cells. While more research is needed to fully understand its role in this process, it is clear that it is involved.

Studies have shown that CD300A is highly expressed in cancer stem cells, and that it plays a role in their development. This suggests that CD300A may be a potential drug target for cancer stem cell-based therapies.

In addition to its role in cancer stem cells, CD300A is also being investigated as a potential biomarker for the disease. Its expression has been shown to be associated with the severity of certain diseases, such as rheumatoid arthritis and multiple sclerosis.

While more research is needed to fully understand the role of CD300A as a drug target and biomarker, it is clear that it has the potential to be a valuable tool in the fight against cancer and other diseases.

Protein Name: CD300a Molecule

Functions: Inhibitory receptor which may contribute to the down-regulation of cytolytic activity in natural killer (NK) cells, and to the down-regulation of mast cell degranulation (PubMed:10746781, PubMed:16339535, PubMed:9701027). Negatively regulates the Toll-like receptor (TLR) signaling mediated by MYD88 but not TRIF through activation of PTPN6 (PubMed:22043923)

The "CD300A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD300A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73